




**RetinaPharma Technologies, Inc.**

Founded in 1998 and located in Jenkintown, PA, RetinaPharma Technologies, Inc. is an early stage biotechnology company that is developing products for the prevention, treatment and diagnosis of vision disorders and eye diseases that affect over 19.5 million people in the United States and Western Europe. Its mission is to offer clinically beneficial and incrementally superior pharmaceuticals and related devices based on the company's proprietary technology. Supporting this mission are 13 issued U.S. patents with others pending. In addition to being selected by BioAdvance to receive a Greenhouse Fund investment, RetinaPharma has also received a major grant from the Ben Franklin Technology Partners.

**Proposed Project**

The initial product development focus is on devices and pharmaceuticals for glaucoma and age-related macular degeneration (AMD). Products under development include:

- TonoPach™ - an inexpensive and novel device used to measure intraocular pressure in millions of patients who are improperly diagnosed for glaucoma as a result of disease or LASIK surgery. BioAdvance is funding development of a prototype of the TonoPach.
- PhotoTarget® system - a targeted, thermally-sensitive drug delivery pharmaceutical (liposome vesicles) and associated devices with the potential to redefine the standard of care for "WET" AMD.
- Desmethyldeprenyl - an oral, neuro-protective agent shown to interrupt cellular signaling pathways that would normally cause apoptosis (programmed cell death). It's expected to be a potent drug to combat glaucoma, AMD and certain other diseases.



Concept drawing of TonoPach™

**Management**

**Terry A. Fuller, Ph.D.**, President and Chief Executive Officer is the co-founder, entrepreneur and executive in emerging and high-growth start-up and early stage pharmaceutical and medical device companies. He has held positions of Chief Executive Officer, Chief Operating Officer, and Executive Vice President of Technology for both public and private corporations, including at IOLab (NYSE: JNJ), Surgical Laser Technologies (NASDAQ: SLTI), Laser Skin Toner, and SubLase. He has 14 issued U.S. patents.

**Mark Dorfman, C.P.A.**, Chief Financial Officer, was formerly with Allegheny Health Systems and Robec, Inc., a high-growth publicly traded computer distribution company that grew from \$35 million to over \$200 million under his management.

**Chris Chapman, M.D.**, Director of Medical and Regulatory Affairs is an experienced executive formerly with Quintiles Consulting and was instrumental in achieving FDA approval of many drugs, including Corolopam®, Agrylin™, Zyvox®, Arava™, and Integrilin®.

For more information, contact: Terry Fuller, Ph.D., President and Chief Executive Officer, RetinaPharma Technologies, Inc., 944 Morgan Road, Jenkintown, PA 19046, e: TAFuller@RetinaPharma.com, p: (215) 885-4558 Ext. 11, f: (215) 885-2788, www.RetinaPharm.com